JP2010527981A - 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 - Google Patents

癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 Download PDF

Info

Publication number
JP2010527981A
JP2010527981A JP2010508909A JP2010508909A JP2010527981A JP 2010527981 A JP2010527981 A JP 2010527981A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010527981 A JP2010527981 A JP 2010527981A
Authority
JP
Japan
Prior art keywords
alkyl
heterocyclyl
aryl
cancer
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527981A5 (enExample
Inventor
マーク・ジェイムズ・オコナー
グリーム・キャメロン・マーレー・スミス
ソーニャ・ザブルドフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010527981A publication Critical patent/JP2010527981A/ja
Publication of JP2010527981A5 publication Critical patent/JP2010527981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010508909A 2007-05-25 2008-05-23 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 Pending JP2010527981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (2)

Publication Number Publication Date
JP2010527981A true JP2010527981A (ja) 2010-08-19
JP2010527981A5 JP2010527981A5 (enExample) 2011-06-30

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508909A Pending JP2010527981A (ja) 2007-05-25 2008-05-23 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤

Country Status (11)

Country Link
US (1) US20100249112A1 (enExample)
EP (1) EP2167086A1 (enExample)
JP (1) JP2010527981A (enExample)
KR (1) KR20100020981A (enExample)
CN (1) CN101743003A (enExample)
AU (1) AU2008256562A1 (enExample)
BR (1) BRPI0811059A2 (enExample)
CA (1) CA2687786A1 (enExample)
MX (1) MX2009012705A (enExample)
RU (1) RU2009147819A (enExample)
WO (1) WO2008146035A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR102645511B1 (ko) * 2017-04-10 2024-03-08 시에라 온코로지 엘엘씨 종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
WO2005066163A2 (en) * 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
JP2006519827A (ja) * 2003-03-12 2006-08-31 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519827A (ja) * 2003-03-12 2006-08-31 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
WO2005066163A2 (en) * 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013001920; Ｃｅｌｌ　Ｃｙｃｌｅ Ｖｏｌ．５，Ｎｏ．２０, 2006, ｐ２３６４-２３７０ *

Also Published As

Publication number Publication date
KR20100020981A (ko) 2010-02-23
US20100249112A1 (en) 2010-09-30
CN101743003A (zh) 2010-06-16
WO2008146035A1 (en) 2008-12-04
BRPI0811059A2 (pt) 2017-05-09
MX2009012705A (es) 2009-12-08
RU2009147819A (ru) 2011-06-27
CA2687786A1 (en) 2008-12-04
AU2008256562A1 (en) 2008-12-04
EP2167086A1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
US20100249112A1 (en) Combination of chk and parp inhibitors for the treatment of cancers
AU2011288876B2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
CA2819410C (en) Substituted phthalazin-1(2h)-ones, preparation processes and medical uses thereof
JP4268651B2 (ja) フタラジノン誘導体
ES2878130T3 (es) Derivados de purina y deazapurina como compuestos farmacéuticos
CA3213029A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
BR112013013435B1 (pt) composto, composição farmacêutica, uso de um composto,e, processo para a preparação de um composto
JP2009512671A (ja) ４−ヘテロアリールメチル置換されたフタラジノン誘導体
JP2010532339A (ja) Ｐａｒｐ−１の阻害剤としてのフタラジノン誘導体
BR112020019824A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
CN101981013A (zh) 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
TW200900396A (en) Phthalazinone derivatives
WO2023192416A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
US20040127504A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN112237579A (zh) 药物组合及其用途
CN105102447B (zh) 双环取代的嘧啶类pde‑5抑制剂的前药
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
KR20180019443A (ko) 1,6-이치환된 인돌 화합물을 함유하는 약물 내성 및 부작용이 저감된 만성골수성백혈병 치료제
WO2016153394A1 (ru) Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
HK40035225A (en) Pharmaceutical combination and use thereof
HK1212338B (en) Bicyclic substituted pyrimidine pde-5 inhibitor prodrug
JP2010527982A (ja) 癌の処置のためのチェックポイントキナーゼ（ｃｈｋ）および毛細血管拡張性変異（ａｔｍ）阻害剤の組み合わせ物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702